Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy BioCryst Pharmaceuticals stock

Learn how to easily invest in BioCryst Pharmaceuticals stock.

BioCryst Pharmaceuticals Inc is a biotechnology business based in the US. BioCryst Pharmaceuticals shares (BCRX) are listed on the NASDAQ and all prices are listed in US Dollars. BioCryst Pharmaceuticals employs 358 staff and has a trailing 12-month revenue of around $203.6 million.

How to buy shares in BioCryst Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BCRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

BioCryst Pharmaceuticals stock price (NASDAQ: BCRX)

Use our graph to track the performance of BCRX stocks over time.

BioCryst Pharmaceuticals shares at a glance

Information last updated 2022-09-24.
Latest market close$12.60
52-week range$7.61 - $19.99
50-day moving average $13.16
200-day moving average $13.07
Wall St. target price$18.30
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.07

Buy BioCryst Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy BioCryst Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioCryst Pharmaceuticals price performance over time

Historical closes compared with the close of $12.6 from 2022-09-30

1 week (2022-09-26) 4.05%
1 month (2022-09-02) -10.45%
3 months (2022-07-01) 16.24%
6 months (2022-04-01) -24.05%
1 year (2021-10-01) -8.23%
2 years (2020-10-02) 273.89%
3 years (2019-10-03) 364.94%
5 years (2017-10-02) 136.40%

BioCryst Pharmaceuticals financials

Revenue TTM $203.6 million
Gross profit TTM $-58,902,000
Return on assets TTM -28.79%
Return on equity TTM -1925.37%
Profit margin -102.96%
Book value $0.19
Market capitalisation $2.4 billion

TTM: trailing 12 months

BioCryst Pharmaceuticals share dividends

We're not expecting BioCryst Pharmaceuticals to pay a dividend over the next 12 months.

BioCryst Pharmaceuticals share price volatility

Over the last 12 months, BioCryst Pharmaceuticals's shares have ranged in value from as little as $7.61 up to $19.99. A popular way to gauge a stock's volatility is its "beta".

BCRX.US volatility(beta: 2.08)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioCryst Pharmaceuticals's is 2.0771. This would suggest that BioCryst Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

BioCryst Pharmaceuticals overview

BioCryst Pharmaceuticals, Inc. , a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co. , Ltd. ; Seqirus UK Limited; Shionogi & Co.

Frequently asked questions

What percentage of BioCryst Pharmaceuticals is owned by insiders or institutions?
Currently 0.966% of BioCryst Pharmaceuticals shares are held by insiders and 83.013% by institutions.
How many people work for BioCryst Pharmaceuticals?
Latest data suggests 358 work at BioCryst Pharmaceuticals.
When does the fiscal year end for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals's fiscal year ends in December.
Where is BioCryst Pharmaceuticals based?
BioCryst Pharmaceuticals's address is: 4505 Emperor Boulevard, Durham, NC, United States, 27703
What is BioCryst Pharmaceuticals's ISIN number?
BioCryst Pharmaceuticals's international securities identification number is: US09058V1035
What is BioCryst Pharmaceuticals's CUSIP number?
BioCryst Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 09058V103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site